Hospital
WRMC Hospital Operating Corporation
WRMC Hospital Operating Corporation was paid $9.43M by Medicaid between Jan 2018 and Dec 2024, across 108 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoWRMC HOSPITAL OPERATING CORPORATION
NORTH WILKESBORO, NC 28659
NORTH WILKESBORO, NC 28659
33aNPI1881614071assigned 07/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.43M
24GClaims221,761
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#52 of 92
Median peer was paid$11.47M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,019 | $880K | |
| 2019 | 32,506 | $922K | |
| 2020 | 19,848 | $445K | |
| 2021 | 25,862 | $1.11M | |
| 2022 | 33,813 | $1.70M | |
| 2023 | 38,623 | $2.05M | |
| 2024incomplete | 38,090 | $2.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 28,016 | 26,206 | $3.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 20,279 | 19,172 | $2.05M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 10% | 6,369 | 5,876 | $947K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,395 | 1,282 | $310K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 7,418 | 6,938 | $259K |
| D2930 | Prefabricated stainless steel crown - primary tooth | 2.5% | 568 | 527 | $235K |
| 80053 | Comprehensive metabolic panel | 1.9% | 21,309 | 19,316 | $181K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 24,537 | 21,989 | $168K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1.8% | 75 | 66 | $167K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 2,407 | 2,189 | $167K |
| J3490 | Unclassified drugs | 1.2% | 11,238 | 6,085 | $114K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 3,754 | 3,343 | $111K |
96 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 2,440 | $90K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,856 | $77K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 84 | $62K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 333 | $61K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 346 | $60K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,012 | $55K |
| D0240 | <1% | 265 | $45K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 226 | $38K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 586 | $35K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 26 | $32K |
| 97597 | <1% | 959 | $28K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 58 | $28K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 552 | $27K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 186 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,327 | $25K |
| 84484 | <1% | 2,533 | $22K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,571 | $22K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,132 | $21K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 192 | $21K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 73 | $19K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,797 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 143 | $16K |
| 81001 | <1% | 4,379 | $14K | |
| D3221 | <1% | 208 | $13K | |
| 87631 | <1% | 151 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 233 | $11K |
| 83690 | <1% | 1,586 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 809 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $10K |
| 81025 | <1% | 1,208 | $10K | |
| 87430 | <1% | 593 | $9K | |
| 86850 | <1% | 653 | $9K | |
| 74018 | <1% | 196 | $9K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 205 | $8K |
| 87807 | <1% | 450 | $7K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 277 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 147 | $6K |
| A9270 | Non-covered item or service | <1% | 38,645 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 56 | $5K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,197 | $5K |
| D1120 | Dental cleaning, child | <1% | 30 | $5K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,341 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 111 | $4K |
| 87081 | <1% | 540 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,439 | $4K |
| D2934 | <1% | 29 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,055 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 595 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 53 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,791 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 70 | $3K |
| 81003 | <1% | 1,509 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 16 | $3K |
| 86900 | <1% | 511 | $3K | |
| D2940 | <1% | 14 | $3K | |
| 83735 | <1% | 376 | $2K | |
| 87088 | <1% | 311 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $2K |
| 83605 | <1% | 214 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 30 | $2K |
| 86901 | <1% | 511 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,163 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 789 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 108 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 171 | $2K |
| 85027 | <1% | 288 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 236 | $2K |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 85 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 257 | $1K |
| 71250 | <1% | 13 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 119 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 27 | $1K |
| 84466 | <1% | 82 | $1K | |
| 82728 | <1% | 73 | $974.20 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,316 | $750.94 |
| 0012A | <1% | 12 | $715.00 | |
| 84439 | <1% | 63 | $560.02 | |
| 83540 | <1% | 82 | $543.80 | |
| 84702 | <1% | 47 | $537.89 | |
| 0011A | <1% | 14 | $520.00 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 70 | $440.37 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 360 | $425.46 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 80 | $302.05 |
| 87420 | <1% | 14 | $262.50 | |
| 85379 | <1% | 26 | $202.44 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 38 | $111.40 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 12 | $100.10 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 44 | $45.57 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 13 | $38.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 31 | $20.91 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $12.37 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 356 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 75 | $0.00 |
| 91301 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, CHAD (PRESIDENT, WILKES MEDICAL CENTER)
| Provider | Location | Paid |
|---|---|---|
| Lexington Medical Center | Lexington, NC | $15.76M |
| Davie Medical Center | Bermuda Run, NC | $818K |
| The Dental Office PC | Sheldon, IA | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.